Digitisation | January 03, 2024
Healthcare Triangle completes US$2 million private placement debt offering
The company received gross proceeds of approximately US$1.7 million and net proceeds,
The company received gross proceeds of approximately US$1.7 million and net proceeds,
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
AMI to become part of Enpro’s Sealing Technologies Segment
Marks remarkable acceleration in innovation using AI technology
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
AHHL is primarily engaged in nursing care, in home primary care, physiotherapy at home, sample collection, post-operative/post-surgical care
US FDA approval based on NEURO-TTRansform Phase III results
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
